Results 281 to 290 of about 6,753,422 (402)
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner +14 more
wiley +1 more source
A Comparative Analysis Between Soft Tissue Manipulation and Pharmacotherapy in TMJ Myofascial Dysfunction Management: A Randomized Controlled Trial. [PDF]
Gurudut P +4 more
europepmc +1 more source
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi +4 more
wiley +1 more source
The Natural Course of Pain in Fibrous Dysplasia/McCune Albright Syndrome: A Prospective Follow Up Study. [PDF]
Bulaicon OO +10 more
europepmc +1 more source
Objective We aimed to validate the Pediatric Arthritis Ultrasound Scoring System (PAUSS) for upper extremity joints in children with juvenile idiopathic arthritis (JIA). Methods Children with JIA were evaluated for elbow, wrist, or finger arthritis by clinical examination (CE) and musculoskeletal ultrasound (MSUS) with images scored according to the ...
Patricia Vega‐Fernandez +12 more
wiley +1 more source
Breathing new life into pain management: a systematic review of nebulised ketamine for analgesia. [PDF]
Kirk D, Whiles E, Jones A, Edmunds C.
europepmc +1 more source
openaire +1 more source
Sex differences in medication discontinuation in axial spondyloarthritis.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall +9 more
wiley +1 more source

